Zeiss Acquires Xradia - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Zeiss Acquires Xradia



Zeiss announced that the acquisition of U.S.-based Xradia, Inc. has been completed and Xradia is now operating under the name of Carl Zeiss X-ray Microscopy, Inc. The acquisition further strengthens the position of the ZEISS Microscopy business group, a manufacturer of light, electron, and X-ray microscopes, with solutions for research and routine inspection in materials and life sciences application fields, the company reports in a press statement.

Zeiss says reports the company will leverage its sales force to make the X-ray technology more accessible in a broader range of applications and workflows. Customers will also benefit from direct service capabilities at multiple locations globally.

http://www.zeiss.de/press/pr0039477b

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here